Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
11.95
+0.53 (4.64%)
Mar 4, 2026, 4:00 PM EST - Market closed
Tenax Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Tenax Therapeutics stock have an average target of 22.5, with a low estimate of 20 and a high estimate of 25. The average target predicts an increase of 88.28% from the current stock price of 11.95.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 17, 2025.
Analyst Ratings
The average analyst rating for Tenax Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $14 → $25 | Strong Buy | Maintains | $14 → $25 | +109.21% | Dec 17, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $20 | Buy | Initiates | $20 | +67.36% | Sep 8, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $15 → $14 | Strong Buy | Maintains | $15 → $14 | +17.15% | Aug 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $16 | Buy | Initiates | $16 | +33.89% | Oct 24, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +33.89% | Oct 14, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.40
from -1.15
EPS Next Year
-1.60
from -1.40
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.43 | -1.50 | ||||
| Avg | -1.40 | -1.60 | ||||
| Low | -1.36 | -1.72 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.